DHR vs. MEDP: Danaher vs. Medpace Stock Comparison

November 11, 2026

How do Danaher (DHR) and Medpace (MEDP) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Danaher (DHR) and Medpace (MEDP) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for Danaher (DHR) and Medpace (MEDP)
Profile Item	DHR	MEDP
Name	Danaher Corp.	Medpace Holdings, Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Life Sciences Tools & Services
GICS Sub-Industry	Life Sciences Tools & Services	Life Sciences Tools & Services
Market Capitalization	161.86 billion USD	18.27 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	December 29, 1978	August 11, 2016
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

DHR

MEDP

GSPC

Danaher (DHR) vs. Medpace (MEDP), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Danaher (DHR) and Medpace (MEDP). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Danaher (DHR) and Medpace (MEDP). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Danaher (DHR) and Medpace (MEDP)
Metric	DHR	MEDP
Total Return (1Y)	11.88%	13.29%
Total Return (3Y, Annualized)	6.67%	35.26%
Total Return (5Y, Annualized)	-2.05%	24.49%

Risk Profile

Drawdown History

DHR

MEDP

GSPC

Danaher (DHR) vs. Medpace (MEDP), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Danaher (DHR) and Medpace (MEDP). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Danaher (DHR) and Medpace (MEDP)
Metric	DHR	MEDP
Volatility (1Y, Annualized)	30.61%	44.16%
Beta (5Y)	0.76	1.10
Max Drawdown (5Y)	-43.31%	-42.87%
Avg. Volume (3M)	3.94M	258.39K

Risk-Adjusted Performance

Risk-Return Positioning

DHR and MEDP are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Danaher (DHR) and Medpace (MEDP)
Metric	DHR	MEDP
Sharpe Ratio (1Y)	0.25	0.20
Sortino Ratio (1Y)	0.35	0.26

Profitability

ROE (TTM)

Both companies show strong equity returns, but Medpace (MEDP) at 117.88% is the standout with ROE above its industry range; Danaher (DHR) at 8.19% also sits in the top quartile.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.19%

Max: 109.18%
DHR: 8.19%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.88%

MEDP: 117.88%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Danaher (DHR) vs. Medpace (MEDP): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Medpace (MEDP) at 18.24% keeps the most of each sales dollar — above its industry’s net margin range — and Danaher (DHR) at 16.91% also retains a top-quartile share.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.91%

Max: 18.05%
DHR: 16.91%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.24%

MEDP: 18.24%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Danaher (DHR) vs. Medpace (MEDP): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Danaher (DHR) at 21.13% and Medpace (MEDP) at 23.12% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.13%

Max: 83.12%
DHR: 21.13%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.12%

Max: 83.12%
MEDP: 23.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Danaher (DHR) vs. Medpace (MEDP): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Danaher (DHR) and Medpace (MEDP)
Metric	DHR	MEDP
ROE (TTM)	8.19%	117.88%
ROA (TTM)	4.06%	18.71%
Net Margin (TTM)	16.91%	18.24%
Operating Margin (TTM)	21.13%	23.12%
Gross Margin (TTM)	59.36%	72.24%

Growth

Revenue Growth

Both Danaher (DHR) at 2.90% and Medpace (MEDP) at 19.97% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Danaher (DHR) vs. Medpace (MEDP): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Danaher (DHR) at -4.54% and Medpace (MEDP) at 20.98% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Danaher (DHR) vs. Medpace (MEDP): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Danaher (DHR) and Medpace (MEDP)
Metric	DHR	MEDP
Revenue Growth (YoY)	2.90%	19.97%
Revenue Growth (3Y CAGR)	-2.67%	20.12%
EPS Growth (YoY)	-4.54%	20.98%
EPS Growth (3Y CAGR)	-19.44%	28.04%

Financial Strength

Current Ratio (MRQ)

Both Danaher (DHR) at 1.63 and Medpace (MEDP) at 0.83 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.63

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
DHR: 1.63
Min: 0.10

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MEDP: 0.83
Min: 0.10

Danaher (DHR) vs. Medpace (MEDP): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Danaher (DHR) at 0.52 and Medpace (MEDP) at 0.29 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.52

Max: 1.42
Q3: 0.65
DHR: 0.52
Median: 0.15
Q1: 0.02
Min: 0.00

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.29

Max: 1.42
Q3: 0.65
MEDP: 0.29
Median: 0.15
Q1: 0.02
Min: 0.00

Danaher (DHR) vs. Medpace (MEDP): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Danaher (DHR) and Medpace (MEDP)
Metric	DHR	MEDP
Current Ratio (MRQ)	1.63	0.83
Debt / Equity (MRQ)	0.52	0.29
Net Debt / EBITDA	2.68	-0.84

Dividends

Dividend Yield (TTM)

Medpace (MEDP) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a yield of 0.67%, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.67%

DHR: 0.67%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Danaher (DHR) vs. Medpace (MEDP): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Medpace (MEDP) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a payout of 25.17%, ranking against industry peers normally.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.17%

DHR: 25.17%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MEDP: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Danaher (DHR) vs. Medpace (MEDP): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Danaher (DHR) and Medpace (MEDP)
Metric	DHR	MEDP
Dividend Yield (TTM)	0.67%	0.00%
Dividend Payout Ratio (TTM)	25.17%	0.00%

Valuation

P/E Ratio (TTM)

Both Danaher (DHR) at 38.12 and Medpace (MEDP) at 36.26 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.12

Max: 85.34
Q3: 43.46
DHR: 38.12
Median: 26.69
Q1: 13.30
Min: 0.07

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.26

Max: 85.34
Q3: 43.46
MEDP: 36.26
Median: 26.69
Q1: 13.30
Min: 0.07

Danaher (DHR) vs. Medpace (MEDP): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Danaher (DHR) at 6.32 and Medpace (MEDP) at 6.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.32

Max: 58.18
Q3: 25.77
Median: 7.30
DHR: 6.32
Q1: 3.01
Min: 0.01

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.44

Max: 58.18
Q3: 25.77
Median: 7.30
MEDP: 6.44
Q1: 3.01
Min: 0.01

Danaher (DHR) vs. Medpace (MEDP): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Danaher (DHR) at 3.02 sits near its industry’s typical P/B ratio, while Medpace (MEDP) at 31.23 prices above its benchmark range — MEDP looks rich relative to book.

DHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.02

Max: 13.53
Q3: 6.54
Median: 3.25
DHR: 3.02
Q1: 1.69
Min: -5.59

MEDP

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.23

MEDP: 31.23
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Danaher (DHR) vs. Medpace (MEDP): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Danaher (DHR) and Medpace (MEDP)
Metric	DHR	MEDP
P/E Ratio (TTM)	38.12	36.26
P/S Ratio (TTM)	6.32	6.44
P/B Ratio (MRQ)	3.02	31.23
Free Cash Flow Yield (TTM)	2.93%	2.72%